November 2022 Midatech Pharma PLC ("Midatech" or the "Company") First Patient Enrolled in Phase 1 Study of MTX-110 (MAGIC-G1 Study) in Patients with Recurrent Glioblastoma Midatech Pharma PLC (AIM: MTPH.L; Nasdaq: MTP),

("Midatech" or the "Company")

First Patient Enrolled in Phase 1 Study of MTX-110

(MAGIC-G1 Study) in Patients with

Recurrent Glioblastoma

Midatech Pharma PLC (AIM: MTPH.L; Nasdaq: MTP),

an R&D biotechnology company focused on improving the bio-delivery and biodistribution of medicines, is pleased to announce the enrolment

of the first patient into its Phase 1 study of MTX110 in recurrent glioblastoma (rGB) (NCT 05324501) at the Preston Robert Tisch Brain

Tumor Center at Duke University, USA.

The Phase I study is an open-label, dose escalation

study designed to assess the feasibility and safety of intermittent infusions of MTX110 administered by convection enhanced delivery (CED)

via implanted refillable pump and catheter. The study aims to recruit two cohorts, each with a minimum of four patients; the first cohort

will receive MTX110 only and the second cohort will receive MTX110 in combination with lomustine.

Midatech has previously reported encouraging results

from a Phase I study of MTX110 in diffuse intrinsic pontine glioma ("DIPG") conducted by University of California, San Francisco

with an additional Phase I study of MTX110 in DIPG conducted by Columbia University expected to report shortly. In addition, a Phase I

study of MTX110 in medulloblastoma is being undertaken at the University of Texas.

MTX110 has been granted Orphan Drug and Fast Track

designations by the FDA and Orphan Medicinal Product designation by EMA.

Commenting, Dmitry Zamoryakhin, MD, MBA, CSO

of Midatech, said: "rGB is a devastating and incurable cancer marked by short survival rates and universal recurrence. A start

of recruitment into the MAGIC-G1 study marks a significant step towards developing a potential new treatment paradigm for patients with

this devastating disease that currently has limited effective treatment options".

Commenting, Annick Desjardins, MD, FRCPC, neuro-ongologist,

professor of neurosurgery and neurology at Duke University and study's principal investigator, said: "We are excited to

be a leading center for the MAGIC-G1 study that is looking to overcome the limited penetration of panobinostat through the blood-brain

barrier by its direct administration into the tumor, thus also potentially avoiding systemic toxicity."

About Glioblastoma (GB)

GB is the most common and devastating primary

malignant brain tumour in adults encompassing 14.3% of all primary brain and central nervous system neoplasms(1). With an incidence

of approximately 3.2 per 100,000 population in the USA, approximately 12,300 people in the USA will be diagnosed with GB per annum. Standard

of care for treatment of GB is typically maximal surgical resection followed by radiotherapy plus concomitant and maintenance temozolomide

chemotherapy with or without the Optune device . Notwithstanding, the multidisciplinary approach, almost all patients experience

tumour progression with nearly universal mortality. The median survival from initial diagnosis is less than 21 months(2).

no standard of care is established for rGB.

MTX110 is a water-soluble

form of panobinostat free base, achieved through complexation with hydroxypropyl- -cyclodextrin (HPBCD), that enables convection-enhanced

delivery (CED) at potentially chemotherapeutic doses directly to the site of the tumour. Panobinostat is a hydroxamic acid and acts as

a non-selective histone deacetylase inhibitor (pan-HDAC inhibitor). The currently available oral formulation of panobinostat lactate (Farydak )

is not suitable for treatment of brain cancers owing to poor blood-brain barrier penetration and inadequate brain drug concentrations.

Based on favourable translational science data, MTX110 is being evaluated clinically as a treatment for DIPG (NCT03566199, NCT04264143)

and recurrent medulloblastoma (NCT04315064), and preclinically for treatment of glioblastoma (SNO 2020 Abstract TMOD-27). MTX110 is delivered

directly into and around the patient's tumour via a catheter system (e.g. CED or fourth ventricle infusions) to bypass the blood-brain

barrier. This technique exposes the tumour to very high drug concentrations while simultaneously minimising systemic drug levels and the

potential for toxicity and other side effects. Panobinostat has demonstrated high potency against DIPG tumour cells in in vitro

and in vivo models, and in a key study it was the most promising of 83 anticancer agents tested in 14 patient-derived DIPG cell

lines (Grasso et al, 2015. Nature Medicine 21(6), 555-559).

(1) Low JT, Ostrom QT, Cioffi G, Neff C, Waite

KA, Kruchko C, Barnholtz-Sloan JS. Primary brain and other central nervous system tumors in the United States (2014-2018): A summary of

the CBTRUS statistical report for clinicians. Neurooncol Pract. 2022 Feb 22;9(3):165-182. doi: 10.1093/nop/npac015. PMID: 35601966; PMCID:

(2) Stupp R, Taillibert S, Kanner AA, et al. Maintenance

Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial. JAMA : the journal

of the American Medical Association. 2015;314(23):2535-2543.

Chinot OL, Wick W, Mason W, et al. Bevacizumab

plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med. 2014;370(8):709-722.

For more information, please contact:

About Midatech Pharma

Midatech Pharma PLC (dual listed on LSE AIM: MTPH;

and NASDAQ: MTP) is a drug delivery technology company focused on improving the bio-delivery and bio-distribution of medicines. The

Company combines approved and development medications with its proprietary and innovative drug delivery technologies to provide compelling

products that have the potential to powerfully impact the lives of patients.

The Company has developed three in-house technology

platforms, each with its own unique mechanism to improve delivery of medications to sites of disease. All of the Company's technologies

have successfully entered human use in the clinic, providing important validation of the potential for each platform:

The platform nature of the technologies offers

the potential to develop multiple drug assets rather than being reliant on a limited number of programmes. Midatech's technologies

are supported by 36 patent families including 120 granted patents and an additional 70 patent applications. Midatech's headquarters and

R&D facility is in Cardiff, UK. For more information please visit www.midatechpharma.com

Forward-Looking Statements

Certain statements in this press release may constitute

"forward-looking statements" within the meaning of legislation in the United Kingdom and/or United States Private Securities

Litigation Reform Act. All statements contained in this press release that do not relate to matters of historical fact should be considered

forward-looking statements.

Reference should be made to those documents that

Midatech shall file from time to time or announcements that may be made by Midatech in accordance with the London Stock Exchange AIM Rules

for Companies ("AIM Rules"), the Disclosure and Transparency Rules ("DTRs") and the rules and regulations promulgated

by the US Securities and Exchange Commission, which contains and identifies other important factors that could cause actual results to

differ materially from those contained in any projections or forward-looking statements. These forward-looking statements speak only as

of the date of this announcement. All subsequent written and oral forward-looking statements by or concerning Midatech are expressly qualified

in their entirety by the cautionary statements above. Except as may be required under the AIM Rules or the DTRs or by relevant law in

the United Kingdom or the United States, Midatech does not undertake any obligation to publicly update or revise any forward-looking statements

because of new information, future events or otherwise arising.